Several methodologies that rely on the detection of immunophenotypic or molecular
abnormalities of the neoplastic cells are now available to quantify measurable (“minimal”) …

Measurable residual disease (MRD) is an important biomarker in acute myeloid leukemia
(AML) that is used for prognostic, predictive, monitoring, and efficacy-response …

Acute myeloid leukemia (AML) is a heterogeneous clonal disease associated with a dismal
survival, partly due to the frequent occurrence of relapse. Many patient-and leukemia …

Quantification of measurable residual disease (MRD) provides critical prognostic information
in acute myeloid leukemia (AML). A variety of platforms exist for MRD detection, varying in …

In recent years there have been major advances in the use of molecular diagnostic and
monitoring techniques for patients with acute myeloid leukaemia (AML). Coupled with the …

Introduction: Acute myeloid leukemia [AML] is a heterogenous group of primary
hematopoietic neoplasms arising from myeloid precursor cells. Up to 50% of patients failed …

The efforts made in the last decade regarding the molecular landscape of acute myeloid
leukemia (AML) have created the possibility of obtaining patients' personalized treatment …

Longitudinal molecular measurable residual disease (MRD) sampling after completion of
therapy serves as a refined tool for identification of imminent relapse of acute myeloid …

Simple Summary Leukemia stem cells (LSCs) are rare cell populations present in acute
myeloid leukemia (AML) that are resistant to chemotherapy and cause disease relapse in …

Core binding factor acute myeloid leukemia (CBF AML), defined by t (8; 21) or inv (16), is a
subset of favorable risk AML. Despite its association with a high complete remission rate …